Identification

Name
Omeprazole
Accession Number
DB00338  (APRD00446)
Type
Small Molecule
Groups
Approved, Investigational, Vet approved
Description

A highly effective inhibitor of gastric acid secretion used in the therapy of stomach ulcers and Zollinger-Ellison syndrome. Omeprazole belongs to a class of antisecretory compounds, the substituted benzimidazoles, that suppress gastric acid secretion by specific inhibition of the H+/K+ ATPase enzyme system at the secretory surface of the gastric parietal cell.

Structure
Thumb
Synonyms
  • OMEP
  • Omeprazol
  • Omeprazolum
Product Ingredients
IngredientUNIICASInChI Key
Omeprazole magnesium426QFE7XLK95382-33-5KWORUUGOSLYAGD-UHFFFAOYSA-N
Omeprazole sodiumKV03YZ6QLW95510-70-6RYXPMWYHEBGTRV-UHFFFAOYSA-N
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Leader OmeprazoleTablet, delayed release20 mg/1OralRemedy Repack2013-06-042017-01-04Us
Losec 10 mgTablet, delayed release10 mgOralAstra Zeneca1997-04-28Not applicableCanada
Losec 20 mgTablet, delayed release20 mgOralAstra Zeneca1996-12-31Not applicableCanada
Losec Capsules 10mgCapsule, delayed release10 mgOralAstra Zeneca2000-10-032013-12-04Canada
Losec Capsules 20mgCapsule, delayed release20 mgOralAstra Zeneca1989-12-31Not applicableCanada
Losec Capsules 40mgCapsule, delayed release40 mgOralAstra Zeneca2003-10-172010-06-30Canada
Losec Mups - 10mgTablet, delayed release10 mgOralAstra Zeneca2001-02-222009-12-01Canada
Losec Mups - 20mgTablet, delayed release20 mgOralAstra Zeneca2001-02-222009-12-01Canada
OmeprazoleCapsule, delayed release20 mgOralSanis Health Inc2010-06-16Not applicableCanada
OmeprazoleCapsule, delayed release20 mgOralSivem Pharmaceuticals Ulc2012-06-10Not applicableCanada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-omeprazoleCapsule, delayed release20 mgOralApotex Corporation2004-01-28Not applicableCanada
Apo-omeprazoleCapsule, delayed release40 mgOralApotex CorporationNot applicableNot applicableCanada
Auro-omeprazoleCapsule, delayed release20 mgOralAuro Pharma Inc2014-03-26Not applicableCanada
Auro-omeprazoleCapsule, delayed release10 mgOralAuro Pharma Inc2014-03-26Not applicableCanada
Ava-omeprazoleCapsule, delayed release20 mgOralAvanstra Inc2011-11-282014-08-21Canada
Bio-omeprazoleTablet, delayed release20 mgOralBiomed Pharma2016-09-07Not applicableCanada
Dom-omeprazole DrTablet, delayed release20 mgOralDominion Pharmacal2013-01-23Not applicableCanada
Dom-omeprazole DrTablet, delayed release10 mgOralDominion PharmacalNot applicableNot applicableCanada
Jamp-omeprazole DrTablet, delayed release20 mgOralJamp Pharma Corporation2014-02-11Not applicableCanada
medPREDkitKitMed Arbor Llc2017-12-252018-01-17Us
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Acid ReducerTablet, delayed release20 mg/1OralWinco Foods, Llc.2018-06-06Not applicableUs
Acid ReducerTablet, delayed release20 mg/1OralFamily Dollar2018-06-06Not applicableUs
Acid ReducerTablet, delayed release20 mg/1OralDiscount Drug Mart2018-06-06Not applicableUs
Acid ReducerTablet, delayed release20 mg/1OralBest Choice2018-06-06Not applicableUs
Acid ReducerCapsule, delayed release20 mg/1OralCardinal Health2017-03-07Not applicableUs
Acid ReducerTablet, delayed release20 mg/1OralAurohealth LLC2018-06-06Not applicableUs
Acid ReducerTablet, delayed release20 mg/1OralBi Mart2018-06-06Not applicableUs
Acid ReducerTablet, delayed release20 mg/1OralAurohealth LLC2018-06-06Not applicableUs
Ahi-omeprazoleTablet, delayed release20 mgOralAccord Healthcare LimitedNot applicableNot applicableCanada
Basic Care OmeprazoleTablet, delayed release20 mg/1OralL. Perrigo Company2017-08-08Not applicableUs
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Good Sense Omeprazole and Sodium BicarbonateOmeprazole (20 mg/1) + Sodium bicarbonate (1100 mg/1)Capsule, gelatin coatedOralL. Perrigo Company2017-06-19Not applicableUs
Not ApplicableOmeprazole (40 mg/1) + Sodium bicarbonate (1100 mg/1)CapsuleOralSterling Knight Pharmaceuticals, Llc2017-07-13Not applicableUs
Omeclamox-PakOmeprazole + Amoxicillin + ClarithromycinKitPernix Therapeutics2012-04-272017-12-22Us
Omeclamox-PakOmeprazole + Amoxicillin + ClarithromycinKitCumberland Pharmaceuticals2012-04-27Not applicableUs
Omeprazole and sodium bicarbonateOmeprazole (20 mg/1) + Sodium bicarbonate (1100 mg/1)Capsule, gelatin coatedOralH.E.B.2017-08-25Not applicableUs
Omeprazole and Sodium BicarbonateOmeprazole (20 mg/1) + Sodium bicarbonate (1100 mg/1)CapsuleOralCadila Pharnmaceuticals2018-07-19Not applicableUs
Omeprazole and Sodium BicarbonateOmeprazole (20 mg/1) + Sodium bicarbonate (1100 mg/1)CapsuleOralNorth Star Rx Llc2016-07-15Not applicableUs
Omeprazole and Sodium BicarbonateOmeprazole (20 mg/1) + Sodium bicarbonate (1100 mg/1)CapsuleOralZydus Pharmaceuticals Usa, Inc.2018-05-29Not applicableUs
Omeprazole and Sodium BicarbonateOmeprazole (40 mg/1) + Sodium bicarbonate (1680 mg/1)Powder, for suspensionOralOceanside Pharmaceuticals2004-06-15Not applicableUs
Omeprazole and Sodium BicarbonateOmeprazole (20 mg/1) + Sodium bicarbonate (1100 mg/1)Capsule, gelatin coatedOralCVS Health2016-07-15Not applicableUs
International/Other Brands
Antra / Audazol / Belmazol / Ceprandal / Danlox / Desec / Elgam / Emeproton / Gasec / Gastrimut / Gastroloc / Indurgan / Inhibitron / Logastric / Losec / Mepral / Mopral / Olexin / Omapren / Omepral / Omeprazon / Omeprol / Omezol / Omisec / Omizac / Ortanol / Parizac / Prazidec / Prazolit / Procelac / Ramezol / Regulacid / Sanamidol / Ulceral / Ulcesep / Ultop / Zepral
Categories
UNII
KG60484QX9
CAS number
73590-58-6
Weight
Average: 345.416
Monoisotopic: 345.114712179
Chemical Formula
C17H19N3O3S
InChI Key
SUBDBMMJDZJVOS-UHFFFAOYSA-N
InChI
InChI=1S/C17H19N3O3S/c1-10-8-18-15(11(2)16(10)23-4)9-24(21)17-19-13-6-5-12(22-3)7-14(13)20-17/h5-8H,9H2,1-4H3,(H,19,20)
IUPAC Name
6-methoxy-2-[(4-methoxy-3,5-dimethylpyridin-2-yl)methanesulfinyl]-1H-1,3-benzodiazole
SMILES
COC1=CC2=C(C=C1)N=C(N2)S(=O)CC1=NC=C(C)C(OC)=C1C

Pharmacology

Indication

Omeprazole is indicated for the treatment of duodenal ulcers, benign gastric ulcers, gastroesophageal reflux disease (GERD), heartburn and other symptoms associated with GERD, erosive esophagitis, and long-term treatment of pathological hypersecretory conditions like Zollinger-Ellison syndrome, multiple endocrine adenomas, and systemic mastocytosis.

Associated Conditions
Pharmacodynamics

After oral administration, the onset of the anti-secretory effect of omeprazole occurs within one hour and maximum effect occurring within two hours. At 24 hours, inhibition of secretion is approximately 50% of maximum and duration of inhibition lasts up to 72 hours. Although omeprazole has a very short plasma half-life, the anti-secretory effect lasts for a long time due to prolonged binding to parietal H+/K+ ATPase enzyme. When the drug has been discontinued, secretory activity will return to baseline over 3-5 days. The inhibitory effect of omeprazole on acid secretion increases with repeated once-daily dosing, reaching a plateau after four days. In studies involving more than 200 patients, serum gastrin levels increased during the first 1 to 2 weeks of once-daily administration of therapeutic doses of omeprazole in parallel with inhibition of acid secretion. Systemic effects of omeprazole in the CNS, cardiovascular and respiratory systems have not been found to date.

Mechanism of action

Omeprazole is a proton pump inhibitor that suppresses gastric acid secretion by specific inhibition of the H+/K+-ATPase in the gastric parietal cell. By acting specifically on the proton pump, omeprazole blocks the final step in acid production, thus reducing gastric acidity.

TargetActionsOrganism
APotassium-transporting ATPase alpha chain 1
inhibitor
Human
UAryl hydrocarbon receptor
agonist
Human
Absorption

The delayed-release capsule are enteric-coated (as omeprazole is acid-labile) so the absorption of omprazole begins once the granules leave the stomach. Absorption is rapid. Peak plasma levels occur within 0.5 - 3.5 hours. The absolute bioavailability (compared with intravenous administration) of the delayed-release capsule is 30-40% at doses of 20 - 40 mg, due to presystemic metabolism. This value increases slightly when given repeatedly. Based on a relative bioavailability study, the AUC and Cmax of PRILOSEC (omeprazole magnesium) for Delayed-Release Oral Suspension were 87% and 88% of those for PRILOSEC Delayed-Release Capsules, respectively. Interestingly, when the 40 mg delayed release capsule is given with or without applesauce, it is bioequivalent. However, when the 20 mg delayed release capsule is given with the same conditions, it is not bioequivalent. When the same capsule is given to the elderly, bioavailability increases. Omeprazole was 76% bioavailable.

Volume of distribution
Not Available
Protein binding

95% bound to human plasma protein.

Metabolism

Hepatic. Omeprazole is extensively metabolized by the cytochrome P450 (CYP) enzyme system. The two primary CYP isozymes involved are CYP2C19 and CYP3A4. Metabolism is stereoselective in which the S-isomer is converted to 5'O-desmethylomeprazole via CYP2C19. CYP3A4 converts the S-isomer to 3-hydroxyomeprazole. The R-isomer is converted to 5-hydroxyomeprazole by CYP2C19. CYP3A4 converts the R-isomer to any four different metabolites: 5-hydroxyomeprazole (5-OH OME), omeprazole sulfone (OME sulfone), 5'-O-desmethylomeprazole (5'-desmethyl OME), and 3-hydroxyomeprazole (3-OH OME).

Route of elimination

Urinary excretion is a primary route of excretion of omeprazole metabolites. Little, if any unchanged drug was excreted in the urine. The majority of the dose (about 77%) was eliminated in urine as at least six metabolites. Two were identified as hydroxyomeprazole and the corresponding carboxylic acid. The remainder of the dose was recovered in the feces.

Half life

0.5-1 hour (healthy subjects, delayed-release capsule); 3 hours (hepatic impairment)

Clearance
  • 500 - 600 mL/min [Total body clearance, healthy subjects, delayed-release capsule]
  • 250 mL/min [Plasma clearance, Geriatric]
  • 70 mL/min [Plasma clearance, Hepatic Impairment]
Toxicity

Symptoms of overdose include confusion, drowsiness, blurred vision, tachycardia, nausea, diaphoresis, flushing, headache, and dry mouth.

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Omeprazole Metabolism PathwayDrug metabolism
Omeprazole Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Interacting Gene/EnzymeAllele nameGenotype(s)Defining Change(s)Type(s)DescriptionDetails
Cytochrome P450 2C19CYP2C19*2(A;A)A Allele, homozygoteEffect Directly StudiedPatients with this genotype have reduced metabolism of omeprazole.Details
Cytochrome P450 2C19CYP2C19*3(A;A)A Allele, homozygoteEffect Directly StudiedPatients with this genotype have reduced metabolism of omeprazole.Details
Cytochrome P450 2C19CYP2C19*2ANot Available681G>AEffect InferredPoor metabolizer, lower dose requirement, improved drug efficacyDetails
Cytochrome P450 2C19CYP2C19*2BNot Available681G>AEffect InferredPoor metabolizer, lower dose requirement, improved drug efficacyDetails
Cytochrome P450 2C19CYP2C19*4Not Available1A>GEffect InferredPoor metabolizer, lower dose requirement, improved drug efficacyDetails
Cytochrome P450 2C19CYP2C19*5Not Available1297C>TEffect InferredPoor metabolizer, lower dose requirement, improved drug efficacyDetails
Cytochrome P450 2C19CYP2C19*6Not Available395G>AEffect InferredPoor metabolizer, lower dose requirement, improved drug efficacyDetails
Cytochrome P450 2C19CYP2C19*7Not Available19294T>AEffect InferredPoor metabolizer, lower dose requirement, improved drug efficacyDetails
Cytochrome P450 2C19CYP2C19*22Not Available557G>C / 991A>GEffect InferredPoor metabolizer, lower dose requirement, improved drug efficacyDetails
Cytochrome P450 2C19CYP2C19*24Not Available99C>T / 991A>G  … show all Effect InferredPoor metabolizer, lower dose requirement, improved drug efficacyDetails
Cytochrome P450 2C19CYP2C19*35Not Available12662A>GEffect InferredPoor metabolizer, lower dose requirement, improved drug efficacyDetails

Interactions

Drug Interactions
DrugInteractionDrug group
(R)-warfarinThe serum concentration of (R)-warfarin can be increased when it is combined with Omeprazole.Experimental
(S)-WarfarinThe serum concentration of (S)-Warfarin can be increased when it is combined with Omeprazole.Experimental, Investigational
4-hydroxycoumarinThe serum concentration of 4-hydroxycoumarin can be increased when it is combined with Omeprazole.Experimental
AbemaciclibThe serum concentration of Abemaciclib can be increased when it is combined with Omeprazole.Approved, Investigational
AbirateroneThe serum concentration of Omeprazole can be increased when it is combined with Abiraterone.Approved
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Omeprazole.Approved, Investigational
AcenocoumarolThe serum concentration of Acenocoumarol can be increased when it is combined with Omeprazole.Approved, Investigational
AcetaminophenThe serum concentration of Omeprazole can be increased when it is combined with Acetaminophen.Approved
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Omeprazole.Approved, Vet Approved
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Omeprazole.Approved
AlbendazoleThe serum concentration of Omeprazole can be increased when it is combined with Albendazole.Approved, Vet Approved
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Omeprazole.Experimental, Investigational
AlectinibThe serum concentration of Omeprazole can be increased when it is combined with Alectinib.Approved, Investigational
Alendronic acidThe therapeutic efficacy of Alendronic acid can be decreased when used in combination with Omeprazole.Approved
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Omeprazole.Approved, Investigational
AlosetronThe metabolism of Omeprazole can be decreased when combined with Alosetron.Approved, Withdrawn
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Omeprazole.Approved, Investigational
AmiodaroneThe serum concentration of Omeprazole can be increased when it is combined with Amiodarone.Approved, Investigational
AmitriptylineThe metabolism of Omeprazole can be decreased when combined with Amitriptyline.Approved
AmlodipineThe serum concentration of Omeprazole can be increased when it is combined with Amlodipine.Approved
AmodiaquineThe serum concentration of Omeprazole can be increased when it is combined with Amodiaquine.Approved, Investigational
AmoxapineThe serum concentration of Omeprazole can be increased when it is combined with Amoxapine.Approved
AmphetamineOmeprazole can cause an increase in the absorption of Amphetamine resulting in an increased serum concentration and potentially a worsening of adverse effects.Approved, Illicit, Investigational
AmprenavirThe serum concentration of Amprenavir can be increased when it is combined with Omeprazole.Approved, Investigational
AmsacrineThe serum concentration of Omeprazole can be increased when it is combined with Amsacrine.Approved, Investigational
AnnamycinThe serum concentration of Omeprazole can be increased when it is combined with Annamycin.Investigational
ApalutamideThe serum concentration of Omeprazole can be decreased when it is combined with Apalutamide.Approved, Investigational
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Omeprazole.Approved
AprepitantThe serum concentration of Omeprazole can be increased when it is combined with Aprepitant.Approved, Investigational
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Omeprazole.Approved, Investigational
ArmodafinilThe metabolism of Omeprazole can be decreased when combined with Armodafinil.Approved, Investigational
Arsenic trioxideThe serum concentration of Arsenic trioxide can be increased when it is combined with Omeprazole.Approved, Investigational
Ascorbic acidThe serum concentration of Ascorbic acid can be increased when it is combined with Omeprazole.Approved, Nutraceutical
AstemizoleThe serum concentration of Omeprazole can be increased when it is combined with Astemizole.Approved, Withdrawn
AsunaprevirThe serum concentration of Asunaprevir can be increased when it is combined with Omeprazole.Approved, Investigational, Withdrawn
AtazanavirOmeprazole can cause a decrease in the absorption of Atazanavir resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
AtorvastatinThe serum concentration of Omeprazole can be increased when it is combined with Atorvastatin.Approved
AvatrombopagThe serum concentration of Avatrombopag can be increased when it is combined with Omeprazole.Approved, Investigational
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Omeprazole.Approved, Investigational
AzelastineThe serum concentration of Omeprazole can be increased when it is combined with Azelastine.Approved
AzithromycinThe serum concentration of Omeprazole can be increased when it is combined with Azithromycin.Approved
Bafilomycin A1The serum concentration of Omeprazole can be increased when it is combined with Bafilomycin A1.Experimental
Bafilomycin B1The serum concentration of Omeprazole can be increased when it is combined with Bafilomycin B1.Experimental
BaricitinibThe serum concentration of Baricitinib can be increased when it is combined with Omeprazole.Approved, Investigational
BelinostatThe serum concentration of Belinostat can be increased when it is combined with Omeprazole.Approved, Investigational
BenazeprilOmeprazole can cause a decrease in the absorption of Benazepril resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
BenazeprilatOmeprazole can cause a decrease in the absorption of Benazeprilat resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
BenzquinamideThe serum concentration of Omeprazole can be increased when it is combined with Benzquinamide.Withdrawn
Benzyl alcoholThe serum concentration of Omeprazole can be increased when it is combined with Benzyl alcohol.Approved
BepridilThe serum concentration of Omeprazole can be increased when it is combined with Bepridil.Approved, Withdrawn
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Omeprazole.Approved, Vet Approved
BicalutamideThe serum concentration of Omeprazole can be increased when it is combined with Bicalutamide.Approved
Biricodar dicitrateThe serum concentration of Omeprazole can be increased when it is combined with Biricodar dicitrate.Investigational
BisacodylThe therapeutic efficacy of Bisacodyl can be decreased when used in combination with Omeprazole.Approved
BoceprevirThe metabolism of Omeprazole can be decreased when combined with Boceprevir.Approved, Withdrawn
BortezomibThe metabolism of Omeprazole can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Omeprazole can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Omeprazole.Approved
Brefeldin AThe serum concentration of Omeprazole can be increased when it is combined with Brefeldin A.Experimental
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Omeprazole.Approved, Investigational
BromocriptineThe serum concentration of Omeprazole can be increased when it is combined with Bromocriptine.Approved, Investigational
BromperidolThe serum concentration of Bromperidol can be increased when it is combined with Omeprazole.Approved, Investigational
BuprenorphineThe serum concentration of Omeprazole can be increased when it is combined with Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe serum concentration of Omeprazole can be increased when it is combined with Buspirone.Approved, Investigational
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Omeprazole.Approved
CaffeineThe serum concentration of Omeprazole can be increased when it is combined with Caffeine.Approved
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Omeprazole.Experimental
CanagliflozinThe serum concentration of Canagliflozin can be increased when it is combined with Omeprazole.Approved
CaptoprilOmeprazole can cause a decrease in the absorption of Captopril resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CarbamazepineThe metabolism of Omeprazole can be increased when combined with Carbamazepine.Approved, Investigational
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Omeprazole.Approved, Investigational
CarvedilolThe serum concentration of Omeprazole can be increased when it is combined with Carvedilol.Approved, Investigational
CefditorenThe serum concentration of Cefditoren can be decreased when it is combined with Omeprazole.Approved, Investigational
CefoperazoneThe serum concentration of Omeprazole can be increased when it is combined with Cefoperazone.Approved, Investigational
CeftriaxoneThe serum concentration of Omeprazole can be increased when it is combined with Ceftriaxone.Approved
CefuroximeThe serum concentration of Cefuroxime can be decreased when it is combined with Omeprazole.Approved
CeliprololThe serum concentration of Celiprolol can be increased when it is combined with Omeprazole.Approved, Investigational
CeritinibThe serum concentration of Omeprazole can be increased when it is combined with Ceritinib.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Omeprazole.Approved, Withdrawn
Cerliponase alfaThe serum concentration of Cerliponase alfa can be increased when it is combined with Omeprazole.Approved, Investigational
ChlorambucilThe serum concentration of Chlorambucil can be increased when it is combined with Omeprazole.Approved
ChloramphenicolThe metabolism of Omeprazole can be decreased when combined with Chloramphenicol.Approved, Vet Approved
ChloroformThe serum concentration of Omeprazole can be increased when it is combined with Chloroform.Vet Approved
ChloroquineThe serum concentration of Chloroquine can be increased when it is combined with Omeprazole.Approved, Investigational, Vet Approved
ChlorpromazineThe serum concentration of Omeprazole can be increased when it is combined with Chlorpromazine.Approved, Investigational, Vet Approved
ChlorprothixeneThe serum concentration of Omeprazole can be increased when it is combined with Chlorprothixene.Approved, Investigational, Withdrawn
CilazaprilOmeprazole can cause a decrease in the absorption of Cilazapril resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Omeprazole.Approved, Investigational
CimetidineThe serum concentration of Cimetidine can be increased when it is combined with Omeprazole.Approved, Investigational
CiprofloxacinThe metabolism of Omeprazole can be decreased when combined with Ciprofloxacin.Approved, Investigational
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Omeprazole.Approved
CitalopramThe serum concentration of Citalopram can be increased when it is combined with Omeprazole.Approved
ClarithromycinThe metabolism of Omeprazole can be decreased when combined with Clarithromycin.Approved
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Omeprazole.Approved, Illicit
Clodronic AcidThe therapeutic efficacy of Clodronic Acid can be decreased when used in combination with Omeprazole.Approved, Investigational, Vet Approved
ClofazimineThe serum concentration of Omeprazole can be increased when it is combined with Clofazimine.Approved, Investigational
ClomipramineThe metabolism of Omeprazole can be decreased when combined with Clomipramine.Approved, Investigational, Vet Approved
ClonidineThe serum concentration of Clonidine can be increased when it is combined with Omeprazole.Approved
ClopidogrelOmeprazole may decrease the antiplatelet activities of Clopidogrel.Approved
ClorindioneThe serum concentration of Clorindione can be increased when it is combined with Omeprazole.Experimental
ClotrimazoleThe metabolism of Omeprazole can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe serum concentration of Clozapine can be decreased when it is combined with Omeprazole.Approved
CobicistatThe metabolism of Omeprazole can be decreased when combined with Cobicistat.Approved
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Omeprazole.Approved, Investigational
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Omeprazole.Approved
Concanamycin AThe serum concentration of Omeprazole can be increased when it is combined with Concanamycin A.Experimental
ConivaptanThe serum concentration of Conivaptan can be increased when it is combined with Omeprazole.Approved, Investigational
Conjugated estrogensThe serum concentration of Conjugated estrogens can be increased when it is combined with Omeprazole.Approved
CopanlisibThe serum concentration of Copanlisib can be increased when it is combined with Omeprazole.Approved, Investigational
CrizotinibThe serum concentration of Crizotinib can be increased when it is combined with Omeprazole.Approved
CurcuminThe metabolism of Omeprazole can be decreased when combined with Curcumin.Approved, Investigational
Cyproterone acetateThe serum concentration of Omeprazole can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
CysteamineThe bioavailability of Cysteamine can be decreased when combined with Omeprazole.Approved, Investigational
CytarabineThe serum concentration of Cytarabine can be increased when it is combined with Omeprazole.Approved, Investigational
Dabigatran etexilateThe serum concentration of Dabigatran etexilate can be increased when it is combined with Omeprazole.Approved
DabrafenibThe serum concentration of Omeprazole can be decreased when it is combined with Dabrafenib.Approved, Investigational
DaclatasvirThe serum concentration of Omeprazole can be increased when it is combined with Daclatasvir.Approved, Investigational
DactinomycinThe serum concentration of Omeprazole can be increased when it is combined with Dactinomycin.Approved, Investigational
DanazolThe metabolism of Omeprazole can be decreased when combined with Danazol.Approved
DapagliflozinThe serum concentration of Dapagliflozin can be increased when it is combined with Omeprazole.Approved
DarunavirThe metabolism of Omeprazole can be decreased when combined with Darunavir.Approved
DasabuvirThe serum concentration of Dasabuvir can be increased when it is combined with Omeprazole.Approved
DasatinibOmeprazole can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
DaunorubicinThe serum concentration of Omeprazole can be increased when it is combined with Daunorubicin.Approved
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Omeprazole.Approved, Investigational
DeferasiroxThe serum concentration of Omeprazole can be decreased when it is combined with Deferasirox.Approved, Investigational
DelaprilOmeprazole can cause a decrease in the absorption of Delapril resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
DelavirdineOmeprazole can cause a decrease in the absorption of Delavirdine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
DesipramineThe serum concentration of Omeprazole can be increased when it is combined with Desipramine.Approved, Investigational
DesmethylsertralineThe serum concentration of Omeprazole can be increased when it is combined with Desmethylsertraline.Experimental
DexamethasoneThe serum concentration of Dexamethasone can be increased when it is combined with Omeprazole.Approved, Investigational, Vet Approved
DexmethylphenidateOmeprazole can cause an increase in the absorption of Dexmethylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.Approved, Investigational
DexniguldipineThe serum concentration of Omeprazole can be increased when it is combined with Dexniguldipine.Experimental
DextroamphetamineOmeprazole can cause an increase in the absorption of Dextroamphetamine resulting in an increased serum concentration and potentially a worsening of adverse effects.Approved, Illicit
DexverapamilThe serum concentration of Omeprazole can be increased when it is combined with Dexverapamil.Experimental
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Omeprazole.Approved, Illicit, Investigational, Vet Approved
DicoumarolThe serum concentration of Dicoumarol can be increased when it is combined with Omeprazole.Approved
Diethyl etherThe serum concentration of Omeprazole can be increased when it is combined with Diethyl ether.Experimental
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Omeprazole.Approved, Investigational
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Omeprazole.Approved, Investigational
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Omeprazole.Approved
DihydroergotamineThe serum concentration of Omeprazole can be increased when it is combined with Dihydroergotamine.Approved, Investigational
DiltiazemThe metabolism of Omeprazole can be decreased when combined with Diltiazem.Approved, Investigational
DiphenadioneThe serum concentration of Diphenadione can be increased when it is combined with Omeprazole.Experimental
DipyridamoleThe serum concentration of Omeprazole can be increased when it is combined with Dipyridamole.Approved
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Omeprazole.Approved, Investigational
DofequidarThe serum concentration of Omeprazole can be increased when it is combined with Dofequidar.Experimental, Investigational
DolutegravirOmeprazole can cause a decrease in the absorption of Dolutegravir resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Omeprazole.Approved, Investigational, Vet Approved
DosulepinThe metabolism of Omeprazole can be decreased when combined with Dosulepin.Approved
DovitinibThe serum concentration of Omeprazole can be increased when it is combined with Dovitinib.Investigational
DoxazosinThe serum concentration of Omeprazole can be increased when it is combined with Doxazosin.Approved
DoxepinThe serum concentration of Doxepin can be increased when it is combined with Omeprazole.Approved, Investigational
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Omeprazole.Approved, Investigational
DoxycyclineThe metabolism of Omeprazole can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronabinolThe serum concentration of Omeprazole can be increased when it is combined with Dronabinol.Approved, Illicit
DronedaroneThe serum concentration of Omeprazole can be increased when it is combined with Dronedarone.Approved
DuloxetineThe serum concentration of Omeprazole can be increased when it is combined with Duloxetine.Approved
EconazoleThe serum concentration of Omeprazole can be increased when it is combined with Econazole.Approved
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Omeprazole.Approved
EfavirenzThe metabolism of Omeprazole can be decreased when combined with Efavirenz.Approved, Investigational
ElacridarThe serum concentration of Omeprazole can be increased when it is combined with Elacridar.Investigational
ElagolixThe serum concentration of Elagolix can be increased when it is combined with Omeprazole.Approved, Investigational
ElbasvirThe serum concentration of Elbasvir can be increased when it is combined with Omeprazole.Approved
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Omeprazole.Approved, Investigational
EmopamilThe serum concentration of Omeprazole can be increased when it is combined with Emopamil.Experimental
EnalaprilOmeprazole can cause a decrease in the absorption of Enalapril resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
EnalaprilatOmeprazole can cause a decrease in the absorption of Enalaprilat resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
EnasidenibThe serum concentration of Omeprazole can be increased when it is combined with Enasidenib.Approved, Investigational
EnoxacinThe metabolism of Omeprazole can be decreased when combined with Enoxacin.Approved, Investigational
EnzalutamideThe serum concentration of Omeprazole can be decreased when it is combined with Enzalutamide.Approved
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Omeprazole.Approved, Investigational
ErgonovineThe serum concentration of Omeprazole can be increased when it is combined with Ergonovine.Approved
ErgotamineThe serum concentration of Omeprazole can be increased when it is combined with Ergotamine.Approved
ErlotinibOmeprazole can cause a decrease in the absorption of Erlotinib resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
ErtugliflozinThe serum concentration of Ertugliflozin can be increased when it is combined with Omeprazole.Approved, Investigational
ErythromycinThe serum concentration of Omeprazole can be increased when it is combined with Erythromycin.Approved, Investigational, Vet Approved
EscitalopramThe serum concentration of Escitalopram can be increased when it is combined with Omeprazole.Approved, Investigational
Eslicarbazepine acetateThe metabolism of Omeprazole can be decreased when combined with Eslicarbazepine acetate.Approved
EsomeprazoleThe serum concentration of Omeprazole can be increased when it is combined with Esomeprazole.Approved, Investigational
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Omeprazole.Approved, Investigational, Vet Approved
Estradiol acetateThe serum concentration of Estradiol acetate can be increased when it is combined with Omeprazole.Approved, Investigational, Vet Approved
Estradiol benzoateThe serum concentration of Estradiol benzoate can be increased when it is combined with Omeprazole.Approved, Investigational, Vet Approved
Estradiol cypionateThe serum concentration of Estradiol cypionate can be increased when it is combined with Omeprazole.Approved, Investigational, Vet Approved
Estradiol dienanthateThe serum concentration of Estradiol dienanthate can be increased when it is combined with Omeprazole.Approved, Investigational, Vet Approved
Estradiol valerateThe serum concentration of Estradiol valerate can be increased when it is combined with Omeprazole.Approved, Investigational, Vet Approved
EstramustineThe serum concentration of Omeprazole can be increased when it is combined with Estramustine.Approved, Investigational
EstriolThe serum concentration of Estriol can be increased when it is combined with Omeprazole.Approved, Investigational, Vet Approved
EstroneThe serum concentration of Estrone can be increased when it is combined with Omeprazole.Approved
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Omeprazole.Approved
Ethyl biscoumacetateThe serum concentration of Ethyl biscoumacetate can be increased when it is combined with Omeprazole.Withdrawn
Etidronic acidThe therapeutic efficacy of Etidronic acid can be decreased when used in combination with Omeprazole.Approved
EtoposideThe serum concentration of Omeprazole can be increased when it is combined with Etoposide.Approved
EtravirineThe serum concentration of Omeprazole can be decreased when it is combined with Etravirine.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Omeprazole.Approved
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Omeprazole.Approved
FelodipineThe serum concentration of Omeprazole can be increased when it is combined with Felodipine.Approved, Investigational
FenofibrateThe serum concentration of Omeprazole can be increased when it is combined with Fenofibrate.Approved
FentanylThe serum concentration of Omeprazole can be increased when it is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
Ferric ammonium citrateOmeprazole can cause a decrease in the absorption of Ferric ammonium citrate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Ferric CarboxymaltoseOmeprazole can cause a decrease in the absorption of Ferric Carboxymaltose resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Ferric cationOmeprazole can cause a decrease in the absorption of Ferric cation resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Ferric hydroxideOmeprazole can cause a decrease in the absorption of Ferric hydroxide resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Ferric oxideOmeprazole can cause a decrease in the absorption of Ferric oxide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Ferric pyrophosphateOmeprazole can cause a decrease in the absorption of Ferric pyrophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Ferric subsulfateOmeprazole can cause a decrease in the absorption of Ferric subsulfate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Experimental
Ferric sulfateOmeprazole can cause a decrease in the absorption of Ferric sulfate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Ferrous bisglycinateOmeprazole can cause a decrease in the absorption of Ferrous bisglycinate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Ferrous chlorideOmeprazole can cause a decrease in the absorption of Ferrous chloride resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Ferrous fumarateOmeprazole can cause a decrease in the absorption of Ferrous fumarate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Ferrous gluconateOmeprazole can cause a decrease in the absorption of Ferrous gluconate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Ferrous succinateOmeprazole can cause a decrease in the absorption of Ferrous succinate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Ferrous sulfateOmeprazole can cause a decrease in the absorption of Ferrous sulfate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Experimental
FerumoxidesOmeprazole can cause a decrease in the absorption of Ferumoxides resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
FerumoxsilOmeprazole can cause a decrease in the absorption of Ferumoxsil resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
FerumoxytolOmeprazole can cause a decrease in the absorption of Ferumoxytol resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Omeprazole.Approved
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Omeprazole.Approved, Investigational
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Omeprazole.Approved
Fluciclovine (18F)The serum concentration of Fluciclovine (18F) can be increased when it is combined with Omeprazole.Approved
FluindioneThe serum concentration of Fluindione can be increased when it is combined with Omeprazole.Approved, Investigational
FluoxetineThe metabolism of Omeprazole can be decreased when combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe serum concentration of Flupentixol can be increased when it is combined with Omeprazole.Approved, Investigational, Withdrawn
FluphenazineThe serum concentration of Omeprazole can be increased when it is combined with Fluphenazine.Approved
FlurazepamThe serum concentration of Omeprazole can be increased when it is combined with Flurazepam.Approved, Illicit, Investigational
FluticasoneThe serum concentration of Fluticasone can be increased when it is combined with Omeprazole.Approved, Experimental, Investigational
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Omeprazole.Approved
Fluticasone propionateThe serum concentration of Fluticasone propionate can be increased when it is combined with Omeprazole.Approved
FluvoxamineThe metabolism of Omeprazole can be decreased when combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe metabolism of Omeprazole can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Omeprazole can be increased when it is combined with Fosaprepitant.Approved
FosinoprilOmeprazole can cause a decrease in the absorption of Fosinopril resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
FosinoprilatOmeprazole can cause a decrease in the absorption of Fosinoprilat resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
FosphenytoinThe serum concentration of Fosphenytoin can be increased when it is combined with Omeprazole.Approved, Investigational
Fusidic AcidThe serum concentration of Omeprazole can be increased when it is combined with Fusidic Acid.Approved, Investigational
GallopamilThe serum concentration of Omeprazole can be increased when it is combined with Gallopamil.Investigational
GefitinibOmeprazole can cause a decrease in the absorption of Gefitinib resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
GemfibrozilThe metabolism of Omeprazole can be decreased when combined with Gemfibrozil.Approved
GenisteinThe serum concentration of Omeprazole can be increased when it is combined with Genistein.Investigational
GlecaprevirThe serum concentration of Glecaprevir can be increased when it is combined with Omeprazole.Approved, Investigational
GleptoferronOmeprazole can cause a decrease in the absorption of Gleptoferron resulting in a reduced serum concentration and potentially a decrease in efficacy.Vet Approved
GlyburideThe serum concentration of Glyburide can be increased when it is combined with Omeprazole.Approved
GlycerinThe serum concentration of Omeprazole can be increased when it is combined with Glycerin.Approved, Investigational
Gramicidin DThe serum concentration of Gramicidin D can be increased when it is combined with Omeprazole.Approved
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Omeprazole.Approved
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Omeprazole.Approved, Investigational, Withdrawn
HM-30181The serum concentration of Omeprazole can be increased when it is combined with HM-30181.Experimental
HycanthoneThe serum concentration of Omeprazole can be increased when it is combined with Hycanthone.Approved, Investigational
HydrocodoneThe serum concentration of the active metabolites of Hydrocodone can be reduced when Hydrocodone is used in combination with Omeprazole resulting in a loss in efficacy.Approved, Illicit
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Omeprazole.Approved, Vet Approved
HydroxychloroquineThe serum concentration of Omeprazole can be increased when it is combined with Hydroxychloroquine.Approved
HydroxyureaThe serum concentration of Hydroxyurea can be increased when it is combined with Omeprazole.Approved
IbandronateThe therapeutic efficacy of Ibandronate can be decreased when used in combination with Omeprazole.Approved, Investigational
IbuprofenThe serum concentration of Omeprazole can be increased when it is combined with Ibuprofen.Approved
IdelalisibThe metabolism of Omeprazole can be decreased when combined with Idelalisib.Approved
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Omeprazole.Approved
ImidaprilOmeprazole can cause a decrease in the absorption of Imidapril resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
ImipramineThe metabolism of Omeprazole can be decreased when combined with Imipramine.Approved
Incadronic acidThe therapeutic efficacy of Incadronic acid can be decreased when used in combination with Omeprazole.Approved, Investigational
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Omeprazole.Approved
IndinavirOmeprazole can cause a decrease in the absorption of Indinavir resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
IndomethacinThe serum concentration of Omeprazole can be increased when it is combined with Indomethacin.Approved, Investigational
Inotuzumab ozogamicinThe serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Omeprazole.Approved, Investigational
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Omeprazole.Approved, Investigational
IronOmeprazole can cause a decrease in the absorption of Iron resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Iron DextranOmeprazole can cause a decrease in the absorption of Iron Dextran resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
Iron isomaltoside 1000Omeprazole can cause a decrease in the absorption of Iron isomaltoside 1000 resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Iron saccharateOmeprazole can cause a decrease in the absorption of Iron saccharate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
IsavuconazoleThe serum concentration of Omeprazole can be increased when it is combined with Isavuconazole.Approved, Investigational
IsavuconazoniumThe serum concentration of Omeprazole can be increased when it is combined with Isavuconazonium.Approved, Investigational
IsoniazidThe metabolism of Omeprazole can be decreased when combined with Isoniazid.Approved, Investigational
IsradipineThe serum concentration of Omeprazole can be increased when it is combined with Isradipine.Approved, Investigational
ItraconazoleOmeprazole can cause a decrease in the absorption of Itraconazole resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Omeprazole.Approved, Investigational, Vet Approved
IvosidenibThe serum concentration of Ivosidenib can be increased when it is combined with Omeprazole.Approved, Investigational
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Omeprazole.Approved
KetoconazoleOmeprazole can cause a decrease in the absorption of Ketoconazole resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Omeprazole.Approved, Investigational
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Omeprazole.Approved, Investigational
LaniquidarThe serum concentration of Omeprazole can be increased when it is combined with Laniquidar.Investigational
LansoprazoleThe serum concentration of Lansoprazole can be increased when it is combined with Omeprazole.Approved, Investigational
LapatinibThe serum concentration of Omeprazole can be increased when it is combined with Lapatinib.Approved, Investigational
LedipasvirOmeprazole can cause a decrease in the absorption of Ledipasvir resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Omeprazole.Approved
LenvatinibThe serum concentration of Lenvatinib can be increased when it is combined with Omeprazole.Approved, Investigational
LetermovirThe serum concentration of Letermovir can be increased when it is combined with Omeprazole.Approved, Investigational
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Omeprazole.Approved, Investigational
LevofloxacinThe serum concentration of Levofloxacin can be increased when it is combined with Omeprazole.Approved, Investigational
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Omeprazole.Approved, Investigational
LidocaineThe serum concentration of Omeprazole can be increased when it is combined with Lidocaine.Approved, Vet Approved
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Omeprazole.Approved
LisinoprilOmeprazole can cause a decrease in the absorption of Lisinopril resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
LobeglitazoneThe metabolism of Omeprazole can be decreased when combined with Lobeglitazone.Approved, Investigational
LomerizineThe serum concentration of Omeprazole can be increased when it is combined with Lomerizine.Experimental
LomitapideThe serum concentration of Omeprazole can be increased when it is combined with Lomitapide.Approved, Investigational
LonafarnibThe serum concentration of Omeprazole can be increased when it is combined with Lonafarnib.Investigational
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Omeprazole.Approved
LopinavirThe metabolism of Omeprazole can be decreased when combined with Lopinavir.Approved
LoratadineThe serum concentration of Omeprazole can be increased when it is combined with Loratadine.Approved, Investigational
LorpiprazoleThe serum concentration of Omeprazole can be increased when it is combined with Lorpiprazole.Approved
LosartanThe serum concentration of Losartan can be increased when it is combined with Omeprazole.Approved
LovastatinThe serum concentration of Omeprazole can be increased when it is combined with Lovastatin.Approved, Investigational
LoxapineThe serum concentration of Omeprazole can be increased when it is combined with Loxapine.Approved
LuliconazoleThe serum concentration of Omeprazole can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Omeprazole can be decreased when it is combined with Lumacaftor.Approved
LusutrombopagThe serum concentration of Lusutrombopag can be increased when it is combined with Omeprazole.Approved, Investigational
MefloquineThe serum concentration of Omeprazole can be increased when it is combined with Mefloquine.Approved, Investigational
Megestrol acetateThe serum concentration of Omeprazole can be increased when it is combined with Megestrol acetate.Approved, Investigational, Vet Approved
MelphalanThe serum concentration of Melphalan can be increased when it is combined with Omeprazole.Approved
MemantineOmeprazole may decrease the excretion rate of Memantine which could result in a higher serum level.Approved, Investigational
MesalazineOmeprazole can cause a decrease in the absorption of Mesalazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
MethadoneThe serum concentration of Omeprazole can be increased when it is combined with Methadone.Approved
MethenamineThe therapeutic efficacy of Methenamine can be decreased when used in combination with Omeprazole.Approved, Vet Approved
MethotrexateThe excretion of Methotrexate can be decreased when combined with Omeprazole.Approved
MethylphenidateOmeprazole can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.Approved, Investigational
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Omeprazole.Approved, Vet Approved
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Omeprazole.Approved, Investigational
MetronidazoleThe serum concentration of Omeprazole can be increased when it is combined with Metronidazole.Approved
MexiletineThe metabolism of Omeprazole can be decreased when combined with Mexiletine.Approved, Investigational
MibefradilThe metabolism of Omeprazole can be decreased when combined with Mibefradil.Investigational, Withdrawn
MiconazoleThe serum concentration of Omeprazole can be increased when it is combined with Miconazole.Approved, Investigational, Vet Approved
MidazolamThe serum concentration of Omeprazole can be increased when it is combined with Midazolam.Approved, Illicit
MidostaurinThe metabolism of Omeprazole can be decreased when combined with Midostaurin.Approved, Investigational
MifepristoneThe serum concentration of Omeprazole can be increased when it is combined with Mifepristone.Approved, Investigational
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Omeprazole.Approved
MitomycinThe serum concentration of Mitomycin can be increased when it is combined with Omeprazole.Approved
MitotaneThe serum concentration of Omeprazole can be decreased when it is combined with Mitotane.Approved
MitoxantroneThe serum concentration of Omeprazole can be increased when it is combined with Mitoxantrone.Approved, Investigational
MoclobemideThe metabolism of Omeprazole can be decreased when combined with Moclobemide.Approved, Investigational
ModafinilThe serum concentration of Omeprazole can be decreased when it is combined with Modafinil.Approved, Investigational
MoexiprilOmeprazole can cause a decrease in the absorption of Moexipril resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
MonensinThe serum concentration of Omeprazole can be increased when it is combined with Monensin.Vet Approved
MorphineThe serum concentration of Morphine can be increased when it is combined with Omeprazole.Approved, Investigational
MoxidectinThe serum concentration of Moxidectin can be increased when it is combined with Omeprazole.Approved, Investigational, Vet Approved
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Omeprazole.Approved, Investigational
Mycophenolic acidOmeprazole can cause a decrease in the absorption of Mycophenolic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
NadololThe serum concentration of Nadolol can be increased when it is combined with Omeprazole.Approved
NafcillinThe serum concentration of Omeprazole can be decreased when it is combined with Nafcillin.Approved, Investigational
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Omeprazole.Approved
NaloxoneThe metabolism of Omeprazole can be decreased when combined with Naloxone.Approved, Vet Approved
NefazodoneThe metabolism of Omeprazole can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Nelfinavir can be decreased when it is combined with Omeprazole.Approved
NeostigmineThe serum concentration of Neostigmine can be increased when it is combined with Omeprazole.Approved, Vet Approved
NeratinibThe serum concentration of Omeprazole can be increased when it is combined with Neratinib.Approved, Investigational
NetupitantThe serum concentration of Omeprazole can be increased when it is combined with Netupitant.Approved, Investigational
NevirapineThe metabolism of Omeprazole can be increased when combined with Nevirapine.Approved
NicardipineThe serum concentration of Omeprazole can be increased when it is combined with Nicardipine.Approved, Investigational
NifedipineThe serum concentration of Nifedipine can be increased when it is combined with Omeprazole.Approved
NigericinThe serum concentration of Omeprazole can be increased when it is combined with Nigericin.Experimental
NiguldipineThe serum concentration of Omeprazole can be increased when it is combined with Niguldipine.Experimental
NilotinibOmeprazole can cause a decrease in the absorption of Nilotinib resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
NimodipineThe serum concentration of Omeprazole can be increased when it is combined with Nimodipine.Approved, Investigational
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Omeprazole.Approved
NisoldipineThe serum concentration of Omeprazole can be increased when it is combined with Nisoldipine.Approved
NitrendipineThe serum concentration of Omeprazole can be increased when it is combined with Nitrendipine.Approved, Investigational
NitroprussideOmeprazole can cause a decrease in the absorption of Nitroprusside resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Omeprazole.Approved
OctreotideThe serum concentration of Octreotide can be increased when it is combined with Omeprazole.Approved, Investigational
OdanacatibThe serum concentration of Odanacatib can be increased when it is combined with Omeprazole.Investigational
OlanzapineThe serum concentration of Olanzapine can be increased when it is combined with Omeprazole.Approved, Investigational
OlaparibThe metabolism of Omeprazole can be decreased when combined with Olaparib.Approved
OmapatrilatOmeprazole can cause a decrease in the absorption of Omapatrilat resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Omeprazole.Approved, Investigational
OndansetronThe serum concentration of Ondansetron can be increased when it is combined with Omeprazole.Approved
ONT-093The serum concentration of Omeprazole can be increased when it is combined with ONT-093.Investigational
PaclitaxelThe serum concentration of Omeprazole can be increased when it is combined with Paclitaxel.Approved, Vet Approved
PalbociclibThe serum concentration of Omeprazole can be increased when it is combined with Palbociclib.Approved, Investigational
PaliperidoneThe serum concentration of Paliperidone can be increased when it is combined with Omeprazole.Approved
PamidronateThe therapeutic efficacy of Pamidronate can be decreased when used in combination with Omeprazole.Approved
PanobinostatThe serum concentration of Panobinostat can be increased when it is combined with Omeprazole.Approved, Investigational
PantoprazoleThe serum concentration of Omeprazole can be increased when it is combined with Pantoprazole.Approved
ParitaprevirThe serum concentration of Paritaprevir can be increased when it is combined with Omeprazole.Approved, Investigational
ParoxetineThe serum concentration of Omeprazole can be increased when it is combined with Paroxetine.Approved, Investigational
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Omeprazole.Approved
Peginterferon alfa-2bThe serum concentration of Omeprazole can be increased when it is combined with Peginterferon alfa-2b.Approved
PentazocineThe serum concentration of Pentazocine can be increased when it is combined with Omeprazole.Approved, Vet Approved
PentobarbitalThe metabolism of Omeprazole can be increased when combined with Pentobarbital.Approved, Investigational, Vet Approved
PerflubutaneOmeprazole can cause a decrease in the absorption of Perflubutane resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
PerindoprilOmeprazole can cause a decrease in the absorption of Perindopril resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
PerindoprilatOmeprazole can cause a decrease in the absorption of Perindoprilat resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
PethidineThe serum concentration of Omeprazole can be increased when it is combined with Pethidine.Approved
PhenindioneThe serum concentration of Phenindione can be increased when it is combined with Omeprazole.Approved, Investigational
PhenobarbitalThe metabolism of Omeprazole can be increased when combined with Phenobarbital.Approved, Investigational
PhenothiazineThe serum concentration of Phenothiazine can be increased when it is combined with Omeprazole.Vet Approved
PhenprocoumonThe serum concentration of Phenprocoumon can be increased when it is combined with Omeprazole.Approved, Investigational
PhenytoinThe serum concentration of Omeprazole can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PibrentasvirThe serum concentration of Pibrentasvir can be increased when it is combined with Omeprazole.Approved, Investigational
PimozideThe serum concentration of Omeprazole can be increased when it is combined with Pimozide.Approved
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Omeprazole.Approved
PitolisantThe serum concentration of Pitolisant can be increased when it is combined with Omeprazole.Approved, Investigational
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Omeprazole.Approved
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Omeprazole.Approved, Investigational
PosaconazoleOmeprazole can cause a decrease in the absorption of Posaconazole resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Vet Approved
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Omeprazole.Approved
PrazosinThe serum concentration of Omeprazole can be increased when it is combined with Prazosin.Approved
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Omeprazole.Approved, Vet Approved
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Omeprazole.Approved, Vet Approved
PrimaquineThe serum concentration of Omeprazole can be increased when it is combined with Primaquine.Approved
PrimidoneThe metabolism of Omeprazole can be increased when combined with Primidone.Approved, Vet Approved
ProgesteroneThe serum concentration of Omeprazole can be increased when it is combined with Progesterone.Approved, Vet Approved
PromethazineThe serum concentration of Omeprazole can be increased when it is combined with Promethazine.Approved, Investigational
PropafenoneThe serum concentration of Omeprazole can be increased when it is combined with Propafenone.Approved
PropofolThe serum concentration of Omeprazole can be increased when it is combined with Propofol.Approved, Investigational, Vet Approved
PropranololThe serum concentration of Propranolol can be increased when it is combined with Omeprazole.Approved, Investigational
ProtriptylineThe serum concentration of Omeprazole can be increased when it is combined with Protriptyline.Approved
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Omeprazole.Approved
Prussian blueOmeprazole can cause a decrease in the absorption of Prussian blue resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
QuercetinThe serum concentration of Omeprazole can be increased when it is combined with Quercetin.Experimental, Investigational
QuetiapineThe serum concentration of Quetiapine can be increased when it is combined with Omeprazole.Approved
QuinacrineThe serum concentration of Omeprazole can be increased when it is combined with Quinacrine.Approved, Investigational
QuinaprilOmeprazole can cause a decrease in the absorption of Quinapril resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
QuinaprilatOmeprazole can cause a decrease in the absorption of Quinaprilat resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
QuinidineThe serum concentration of Omeprazole can be increased when it is combined with Quinidine.Approved, Investigational
QuinineThe metabolism of Omeprazole can be increased when combined with Quinine.Approved
RaltegravirOmeprazole can cause an increase in the absorption of Raltegravir resulting in an increased serum concentration and potentially a worsening of adverse effects.Approved
RamiprilOmeprazole can cause a decrease in the absorption of Ramipril resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
RamiprilatOmeprazole can cause a decrease in the absorption of Ramiprilat resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
RanitidineThe serum concentration of Omeprazole can be increased when it is combined with Ranitidine.Approved
ReboxetineThe serum concentration of Omeprazole can be increased when it is combined with Reboxetine.Approved, Investigational
RegorafenibThe serum concentration of Regorafenib can be increased when it is combined with Omeprazole.Approved
RescinnamineOmeprazole can cause a decrease in the absorption of Rescinnamine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ReserpineThe serum concentration of Omeprazole can be increased when it is combined with Reserpine.Approved, Investigational
Reversin 121The serum concentration of Omeprazole can be increased when it is combined with Reversin 121.Experimental
Rhodamine 6GThe serum concentration of Rhodamine 6G can be increased when it is combined with Omeprazole.Experimental
RifampicinThe serum concentration of Omeprazole can be decreased when it is combined with Rifampicin.Approved
RifamycinThe metabolism of Omeprazole can be increased when combined with Rifamycin.Investigational
RifapentineThe metabolism of Omeprazole can be increased when combined with Rifapentine.Approved, Investigational
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Omeprazole.Approved, Investigational
RilpivirineOmeprazole can cause a decrease in the absorption of Rilpivirine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
RimexoloneThe metabolism of Omeprazole can be increased when combined with Rimexolone.Approved
RiociguatOmeprazole can cause a decrease in the absorption of Riociguat resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
RisedronateOmeprazole can cause an increase in the absorption of Risedronate resulting in an increased serum concentration and potentially a worsening of adverse effects.Approved, Investigational
RisedronateThe therapeutic efficacy of Risedronate can be decreased when used in combination with Omeprazole.Approved, Investigational
RisperidoneThe metabolism of Omeprazole can be decreased when combined with Risperidone.Approved, Investigational
RitonavirThe metabolism of Omeprazole can be decreased when combined with Ritonavir.Approved, Investigational
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Omeprazole.Approved
RolapitantThe serum concentration of Omeprazole can be increased when it is combined with Rolapitant.Approved, Investigational
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Omeprazole.Approved, Investigational
RopiniroleThe metabolism of Omeprazole can be decreased when combined with Ropinirole.Approved, Investigational
RucaparibThe serum concentration of Rucaparib can be increased when it is combined with Omeprazole.Approved, Investigational
SalinomycinThe serum concentration of Omeprazole can be increased when it is combined with Salinomycin.Vet Approved
SaquinavirThe serum concentration of Saquinavir can be increased when it is combined with Omeprazole.Approved, Investigational
SarilumabThe therapeutic efficacy of Omeprazole can be decreased when used in combination with Sarilumab.Approved, Investigational
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Omeprazole.Approved
SertralineThe serum concentration of Omeprazole can be increased when it is combined with Sertraline.Approved
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Omeprazole.Approved
SiltuximabThe serum concentration of Omeprazole can be decreased when it is combined with Siltuximab.Approved, Investigational
SimeprevirThe serum concentration of Omeprazole can be increased when it is combined with Simeprevir.Approved
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Omeprazole.Approved
SirolimusThe serum concentration of Sirolimus can be increased when it is combined with Omeprazole.Approved, Investigational
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Omeprazole.Approved, Investigational
Sodium feredetateOmeprazole can cause a decrease in the absorption of Sodium feredetate resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Omeprazole.Approved
SomatostatinThe serum concentration of Somatostatin can be increased when it is combined with Omeprazole.Approved, Investigational
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Omeprazole.Approved, Investigational
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Omeprazole.Approved, Investigational
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Omeprazole.Experimental
SpiraprilOmeprazole can cause a decrease in the absorption of Spirapril resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
St. John's WortThe serum concentration of Omeprazole can be decreased when it is combined with St. John's Wort.Approved, Investigational, Nutraceutical
StanoloneThe serum concentration of Stanolone can be increased when it is combined with Omeprazole.Illicit, Investigational
Stanolone acetateThe serum concentration of Stanolone acetate can be increased when it is combined with Omeprazole.Experimental
StaurosporineThe serum concentration of Omeprazole can be increased when it is combined with Staurosporine.Experimental
StiripentolThe serum concentration of Omeprazole can be increased when it is combined with Stiripentol.Approved
SulpirideThe therapeutic efficacy of Sulpiride can be increased when used in combination with Omeprazole.Approved, Investigational
SumatriptanThe serum concentration of Sumatriptan can be increased when it is combined with Omeprazole.Approved, Investigational
SunitinibThe serum concentration of Sunitinib can be increased when it is combined with Omeprazole.Approved, Investigational
SuvorexantThe serum concentration of Omeprazole can be increased when it is combined with Suvorexant.Approved, Investigational
TacrineThe serum concentration of Tacrine can be increased when it is combined with Omeprazole.Investigational, Withdrawn
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Omeprazole.Approved, Investigational
TalinololThe serum concentration of Talinolol can be increased when it is combined with Omeprazole.Investigational
TamoxifenThe serum concentration of Omeprazole can be increased when it is combined with Tamoxifen.Approved
TariquidarThe serum concentration of Omeprazole can be increased when it is combined with Tariquidar.Investigational
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Omeprazole.Experimental
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Omeprazole.Approved, Investigational
TelaprevirThe metabolism of Omeprazole can be decreased when combined with Telaprevir.Approved, Withdrawn
TelithromycinThe metabolism of Omeprazole can be decreased when combined with Telithromycin.Approved
TelmisartanThe serum concentration of Omeprazole can be increased when it is combined with Telmisartan.Approved, Investigational
TemocaprilOmeprazole can cause a decrease in the absorption of Temocapril resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental, Investigational
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Omeprazole.Approved
TeniposideThe serum concentration of Teniposide can be increased when it is combined with Omeprazole.Approved
TerfenadineThe serum concentration of Omeprazole can be increased when it is combined with Terfenadine.Approved, Withdrawn
TeriflunomideThe serum concentration of Omeprazole can be decreased when it is combined with Teriflunomide.Approved
TesmilifeneThe serum concentration of Omeprazole can be increased when it is combined with Tesmilifene.Investigational
TestosteroneThe serum concentration of Omeprazole can be increased when it is combined with Testosterone.Approved, Investigational
Testosterone cypionateThe serum concentration of Omeprazole can be increased when it is combined with Testosterone cypionate.Approved
Testosterone enanthateThe serum concentration of Omeprazole can be increased when it is combined with Testosterone enanthate.Approved
Testosterone propionateThe serum concentration of Testosterone propionate can be increased when it is combined with Omeprazole.Approved, Investigational, Vet Approved, Withdrawn
Testosterone undecanoateThe serum concentration of Omeprazole can be increased when it is combined with Testosterone undecanoate.Approved, Investigational
TetracyclineThe serum concentration of Tetracycline can be increased when it is combined with Omeprazole.Approved, Vet Approved
Tetraferric tricitrate decahydrateOmeprazole can cause a decrease in the absorption of Tetraferric tricitrate decahydrate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
TetrandrineThe serum concentration of Omeprazole can be increased when it is combined with Tetrandrine.Experimental
TheophyllineThe metabolism of Omeprazole can be decreased when combined with Theophylline.Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Omeprazole.Approved, Withdrawn
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Omeprazole.Approved
TiclopidineThe metabolism of Omeprazole can be decreased when combined with Ticlopidine.Approved
Tiludronic acidThe therapeutic efficacy of Tiludronic acid can be decreased when used in combination with Omeprazole.Approved, Investigational, Vet Approved
TimololThe serum concentration of Timolol can be increased when it is combined with Omeprazole.Approved
TioclomarolThe serum concentration of Tioclomarol can be increased when it is combined with Omeprazole.Experimental
TipifarnibThe serum concentration of Omeprazole can be increased when it is combined with Tipifarnib.Investigational
TipranavirThe metabolism of Omeprazole can be decreased when combined with Tipranavir.Approved, Investigational
TocilizumabThe serum concentration of Omeprazole can be decreased when it is combined with Tocilizumab.Approved
TolevamerThe therapeutic efficacy of Tolevamer can be decreased when used in combination with Omeprazole.Approved, Investigational
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Omeprazole.Approved
TopiramateThe serum concentration of Topiramate can be increased when it is combined with Omeprazole.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Omeprazole.Approved, Investigational
ToremifeneThe serum concentration of Omeprazole can be increased when it is combined with Toremifene.Approved, Investigational
TrandolaprilOmeprazole can cause a decrease in the absorption of Trandolapril resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Omeprazole.Approved, Investigational
TrifluoperazineThe serum concentration of Omeprazole can be increased when it is combined with Trifluoperazine.Approved, Investigational
TriflupromazineThe serum concentration of Omeprazole can be increased when it is combined with Triflupromazine.Approved, Vet Approved
TrimethoprimThe serum concentration of Omeprazole can be increased when it is combined with Trimethoprim.Approved, Vet Approved
TrimipramineThe serum concentration of Trimipramine can be increased when it is combined with Omeprazole.Approved
TroleandomycinThe metabolism of Omeprazole can be decreased when combined with Troleandomycin.Approved
UbidecarenoneThe serum concentration of Ubidecarenone can be increased when it is combined with Omeprazole.Approved, Investigational, Nutraceutical
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Omeprazole.Approved
ValinomycinThe serum concentration of Valinomycin can be increased when it is combined with Omeprazole.Experimental
ValspodarThe serum concentration of Valspodar can be increased when it is combined with Omeprazole.Investigational
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Omeprazole.Approved
VelpatasvirThe serum concentration of Velpatasvir can be increased when it is combined with Omeprazole.Approved, Investigational
VemurafenibThe serum concentration of Omeprazole can be increased when it is combined with Vemurafenib.Approved
VenetoclaxThe serum concentration of Venetoclax can be increased when it is combined with Omeprazole.Approved, Investigational
VenlafaxineThe serum concentration of Venlafaxine can be increased when it is combined with Omeprazole.Approved
VerapamilThe serum concentration of Omeprazole can be increased when it is combined with Verapamil.Approved
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Omeprazole.Approved
VincristineThe excretion of Vincristine can be decreased when combined with Omeprazole.Approved, Investigational
VinflunineThe serum concentration of Vinflunine can be increased when it is combined with Omeprazole.Approved, Investigational
VinorelbineThe serum concentration of Vinorelbine can be increased when it is combined with Omeprazole.Approved, Investigational
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Omeprazole.Approved, Investigational
VoacamineThe serum concentration of Omeprazole can be increased when it is combined with Voacamine.Approved, Investigational
VorapaxarThe serum concentration of Omeprazole can be increased when it is combined with Vorapaxar.Approved
VoriconazoleThe metabolism of Omeprazole can be decreased when combined with Voriconazole.Approved, Investigational
VoxilaprevirThe serum concentration of Voxilaprevir can be increased when it is combined with Omeprazole.Approved, Investigational
WarfarinThe serum concentration of Warfarin can be increased when it is combined with Omeprazole.Approved
YohimbineThe serum concentration of Omeprazole can be increased when it is combined with Yohimbine.Approved, Investigational, Vet Approved
ZafirlukastThe metabolism of Omeprazole can be decreased when combined with Zafirlukast.Approved, Investigational
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Omeprazole.Approved
ZiprasidoneThe metabolism of Omeprazole can be decreased when combined with Ziprasidone.Approved
ZofenoprilOmeprazole can cause a decrease in the absorption of Zofenopril resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Zoledronic acidThe therapeutic efficacy of Zoledronic acid can be decreased when used in combination with Omeprazole.Approved
ZomepiracThe serum concentration of Omeprazole can be increased when it is combined with Zomepirac.Withdrawn
ZosuquidarThe serum concentration of Omeprazole can be increased when it is combined with Zosuquidar.Investigational
ZucapsaicinThe metabolism of Omeprazole can be decreased when combined with Zucapsaicin.Approved, Investigational
Food Interactions
  • Avoid alcohol.
  • Take 30-60 minutes before meals.

References

Synthesis Reference

Arne E. Brandstrom, Bo R. Lamm, "Processes for the preparation of omeprazole and intermediates therefore." U.S. Patent US4620008, issued October, 1982.

US4620008
General References
  1. Yang YX, Lewis JD, Epstein S, Metz DC: Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA. 2006 Dec 27;296(24):2947-53. [PubMed:17190895]
External Links
Human Metabolome Database
HMDB0001913
KEGG Drug
D00455
KEGG Compound
C07324
PubChem Compound
4594
PubChem Substance
46509065
ChemSpider
4433
BindingDB
50241343
ChEBI
77260
ChEMBL
CHEMBL1503
Therapeutic Targets Database
DAP000180
PharmGKB
PA450704
IUPHAR
4279
Guide to Pharmacology
GtP Drug Page
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Omeprazole
ATC Codes
A02BD05 — Omeprazole, amoxicillin and clarithromycinA02BD01 — Omeprazole, amoxicillin and metronidazoleA02BC01 — Omeprazole
AHFS Codes
  • 56:28.36 — Proton-pump Inhibitors
FDA label
Download (218 KB)
MSDS
Download (73.8 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0CompletedBasic ScienceHealthy Volunteers2
0CompletedPreventionLong Segment Barrett's Esophagus / Short Segment Barrett's Esophagus1
0WithdrawnTreatmentEsophagitis1
1Active Not RecruitingOtherNeoplasms1
1Active Not RecruitingTreatmentAdvanced Solid Tumors / Lymphoma, Large B-Cell, Diffuse (DLBCL) / Mantle Cell Lymphoma (MCL) / Marginal Zone Lymphoma / Primary Mediastinal Lymphoma1
1Active Not RecruitingTreatmentBreast Neoplasm, Male / Neoplasms, Breast / Triple Negative Breast Cancer (TNBC)1
1Active Not RecruitingTreatmentNeoplasms1
1CompletedNot AvailableAlzheimer's Disease (AD) / Huntington's Disease (HD)1
1CompletedNot AvailableClostridium Difficile Infection (CDI) / Healthy Volunteers1
1CompletedNot AvailableDrug Interactions1
1CompletedNot AvailableGastric Acid-related Disorders / HCV Infections1
1CompletedNot AvailableHealthy Volunteers5
1CompletedNot AvailableHuman Immunodeficiency Virus (HIV) Infections1
1CompletedNot AvailablePain, Chronic1
1CompletedNot AvailablePharmacodynamics Study1
1CompletedBasic Science(t1/2,λz) / Cmax / Pharmacokinetics / Plasma [AUC(0-672)] / Plasma [AUC(0-t)] / Plasma AUC / Tmax1
1CompletedBasic ScienceAlzheimer's Disease (AD) / Metabolism1
1CompletedBasic ScienceAtopic Dermatitis (AD)1
1CompletedBasic ScienceBioequivalence, AUC, Cmax, Pharmacokinetics1
1CompletedBasic ScienceDrug Interactions1
1CompletedBasic ScienceDrug-Drug Interaction (DDI)1
1CompletedBasic ScienceEvaluation of Pharmacokinetics of Sativex in the Absence and Presence of a CYP2C19 Inhibitor / Evaluation of Pharmacokinetics of Sativex in the Absence and Presence of a Known Inducer of CYP3A4 / Evaluation of Pharmacokinetics of Sativex in the Absence and Presence of a Potent Inhibitor of CYP3A41
1CompletedBasic ScienceGastric Ulcer (GU)1
1CompletedBasic ScienceHealthy Volunteers8
1CompletedBasic ScienceHealthy Volunteers / Pharmacologic Actions1
1CompletedBasic SciencePharmacodynamics of ASP8477 / Pharmacokinetics of ASP84771
1CompletedBasic SciencePharmacokinetic Assessments in Healthy Volunteers1
1CompletedBasic ScienceReflux Esophagitis (RE)1
1CompletedBasic ScienceRheumatoid Arthritis2
1CompletedDiagnosticCytochrome / Pharmacokinetics1
1CompletedDiagnosticDrug Interactions1
1CompletedDiagnosticHealthy Volunteers1
1CompletedHealth Services ResearchHealthy Volunteers1
1CompletedOtherHealthy Volunteers3
1CompletedOtherHealthy Volunteers / Rheumatoid Arthritis1
1CompletedOtherTumors, Solid1
1CompletedSupportive CareHealthy Volunteers1
1CompletedTreatmentAcid Reflux / Gastro Oesophageal Reflux Disease1
1CompletedTreatmentAdult Solid Neoplasm1
1CompletedTreatmentAdvanced Solid Tumors, Excluding Breast Cancer1
1CompletedTreatmentAnemias / Healthy Volunteers1
1CompletedTreatmentCastration Resistant Prostate Cancer (CRPC) / Pharmacokinetics of MDV31001
1CompletedTreatmentChronic Hepatitis C Virus (HCV) Infection1
1CompletedTreatmentCrohn's Disease (CD)1
1CompletedTreatmentDiabetes Mellitus (DM) / Healthy Volunteers1
1CompletedTreatmentDrug Interaction of Clopidogrel1
1CompletedTreatmentDrug Interactions1
1CompletedTreatmentErectile Dysfunction (ED)1
1CompletedTreatmentGastric Ulcer (GU) / Reflux, Gastroesophageal1
1CompletedTreatmentHealthy Volunteers27
1CompletedTreatmentHeartburn1
1CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections1
1CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Infection, Human Immunodeficiency Virus I1
1CompletedTreatmentInfectious Diseases1
1CompletedTreatmentNon-Hodgkin's Lymphoma (NHL) / Tumors1
1CompletedTreatmentProton Pubm Inhibitor / Reflux, Gastroesophageal / Sclerosis, Progressive Systemic1
1CompletedTreatmentPsoriasis2
1CompletedTreatmentPulmonary Disease, Chronic Obstructive1
1CompletedTreatmentReflux, Gastroesophageal1
1CompletedTreatmentTumors, Solid2
1Not Yet RecruitingOtherHepatitis C Viral Infection / Swallowing Disorders1
1Not Yet RecruitingTreatmentAtopic Dermatitis (AD)1
1Not Yet RecruitingTreatmentHeathy Volunteer1
1RecruitingOtherCrohn's Disease (CD)1
1RecruitingTreatmentGastro Esophageal Reflux Disorder / Gastroesophageal Reflux Disorder1
1RecruitingTreatmentTumors, Solid1
1TerminatedTreatmentHealthy Volunteers1
1Unknown StatusTreatmentGlaucoma1
1WithdrawnTreatmentHealthy Volunteers1
1WithdrawnTreatmentLaryngomalacia1
1WithdrawnTreatmentObstructive Sleep Apnea (OSA) / Reflux, Gastroesophageal / Upper Airway Resistance Syndrome1
1WithdrawnTreatmentTumors, Solid1
1, 2CompletedTreatmentAutism Spectrum Conditions/Disorders / Gastrointestinal Problems1
1, 2CompletedTreatmentBacterial Infection Due to Helicobacter Pylori (H. Pylori)1
1, 2CompletedTreatmentCentral Serous Chorioretinopathy (CSC)1
1, 2CompletedTreatmentUlcerative Colitis (UC)1
1, 2RecruitingTreatmentCrohn's Disease (CD)1
2Active Not RecruitingTreatmentIntestinal Colonization With Multidrug-resistant Bacteria1
2Active Not RecruitingTreatmentSquamous Cell Carcinoma of the Oral Cavity1
2CompletedNot AvailableReflux, Gastroesophageal1
2CompletedTreatmentColorectal Cancers1
2CompletedTreatmentDuodenal Ulcer1
2CompletedTreatmentFatty Liver / Insulin Resistance / Liver Dysfunction1
2CompletedTreatmentGastrinoma / Zollinger-Ellison Syndrome1
2CompletedTreatmentGastro-esophageal Reflux Disease (GERD)1
2CompletedTreatmentIdiopathic Pulmonary Fibrosis (IPF)1
2CompletedTreatmentMalignant Lymphomas2
2CompletedTreatmentNonalcoholic Steatohepatitis1
2CompletedTreatmentPeptic ulcer haemorrhage1
2CompletedTreatmentSquamous Cell Carcinoma of the Head and Neck (SCCHN)1
2Not Yet RecruitingTreatmentNAFLD / NASH - Nonalcoholic Steatohepatitis / Type 2 Diabetes Mellitus1
2Not Yet RecruitingTreatmentNon-erosive Reflux Disease (NERD)1
2RecruitingTreatmentCancer of the Breast1
2RecruitingTreatmentCervical Squamous Cell Carcinoma In Situ / Vulvar High Grade Squamous Intraepithelial Lesion1
2RecruitingTreatmentCystic Fibrosis (CF) / Pancreatic Insufficiency1
2TerminatedTreatmentIndigestion1
2WithdrawnTreatmentCancer of Head and Neck1
2WithdrawnTreatmentContact Ulcer of Vocal Folds / Granuloma / Granuloma of Vocal Cords / Granuloma, Laryngeal1
2, 3CompletedTreatmentNon-erosive Reflux Disease (NERD)1
3Active Not RecruitingTreatmentGastro-esophageal Reflux Disease (GERD)1
3Active Not RecruitingTreatmentMyocardial Injury After Noncardiac Surgery (MINS)1
3CompletedNot AvailableGastric Acid / Human Experimentation2
3CompletedNot AvailableIntragastric Acidity1
3CompletedPreventionAnkylosing Spondylitis (AS) / Osteoarthritis (OA) / Rheumatoid Arthritis1
3CompletedPreventionPrecancerous Gastric Lesions1
3CompletedTreatmentAspirin-Associated Gastric Ulcers1
3CompletedTreatmentBacterial Infection Due to Helicobacter Pylori (H. Pylori)1
3CompletedTreatmentBleeding Peptic Ulcers Disease1
3CompletedTreatmentDuodenal Ulcer1
3CompletedTreatmentErosive Esophagitis(EE)1
3CompletedTreatmentExocrine Pancreatic Insufficiency / Pancreatitis, Chronic / Post-pancreatectomy1
3CompletedTreatmentGastric Ulcer (GU)3
3CompletedTreatmentGastro-esophageal Reflux Disease (GERD)1
3CompletedTreatmentGastroesophageal Reflux Disease / Heartburn1
3CompletedTreatmentHelicobacter Infections1
3CompletedTreatmentHemorrhage, Gastrointestinal1
3CompletedTreatmentHuman Experimentation1
3CompletedTreatmentNeurocysticercosis1
3CompletedTreatmentNon-erosive Reflux Disease (NERD)2
3CompletedTreatmentPeptic Ulcers / Upper Gastrointestinal Hemorrhage1
3CompletedTreatmentPeptic ulcer haemorrhage2
3CompletedTreatmentReflux Esophagitis (RE)2
3CompletedTreatmentReflux, Gastroesophageal1
3RecruitingTreatmentBacterial Infection Due to Helicobacter Pylori (H. Pylori) / Indigestion1
3RecruitingTreatmentGlobus1
3RecruitingTreatmentHelicobacter-associated Gastritis1
3RecruitingTreatmentIndigestion1
3RecruitingTreatmentNon-Bleeding Peptic Ulcers1
3TerminatedHealth Services ResearchCoughing1
3TerminatedTreatmentHelicobacter Infections / Motor Fluctuations / Parkinson's Disease (PD)1
3Unknown StatusPreventionEsophagus, Barrett1
3Unknown StatusTreatmentGastro-esophageal Reflux Disease (GERD)1
3Unknown StatusTreatmentMalignant Neoplasm of Stomach1
3WithdrawnTreatmentDiabetes, Diabetes Mellitus Type 11
4Active Not RecruitingTreatmentAcute Gouty Arthritis1
4Active Not RecruitingTreatmentGastro-esophageal Reflux Disease (GERD)1
4Active Not RecruitingTreatmentReflux, Gastroesophageal1
4CompletedNot AvailableAchlorhydria / Bone destruction / Gastro-esophageal Reflux Disease (GERD) / Hip Fractures1
4CompletedNot AvailableNormal Healthy Subject Population1
4CompletedBasic ScienceHealthy Volunteers1
4CompletedBasic ScienceRejection, Transplant1
4CompletedBasic ScienceTolerance1
4CompletedDiagnosticBacterial Infection Due to Helicobacter Pylori (H. Pylori)1
4CompletedDiagnosticFood Allergy1
4CompletedDiagnosticGastroesophageal Reflux Disease1
4CompletedDiagnosticLaryngopharyngeal Reflux (LPR)1
4CompletedOtherBariatric Surgery Candidate1
4CompletedPreventionMarginal Ulcers1
4CompletedSupportive CareOther Surgical Procedures / Pain1
4CompletedTreatmentChronic Rhinosinusitis (Diagnosis) / Laryngopharyngeal Reflux1
4CompletedTreatmentCompliance / Depression / Indigestion1
4CompletedTreatmentCoronary Artery Disease / Drug Interaction Potentiation / VA Drug Interactions [VA Drug Interaction]1
4CompletedTreatmentErosive Esophagitis(EE)1
4CompletedTreatmentEsophagus, Barrett / Inflammatory Reaction1
4CompletedTreatmentGastric Ulcer (GU)1
4CompletedTreatmentGastro-esophageal Reflux Disease (GERD)1
4CompletedTreatmentHealthy Volunteers1
4CompletedTreatmentHeartburn1
4CompletedTreatmentHemorrhage / Peptic Ulcers1
4CompletedTreatmentHypoalbuminemia / Peptic Ulcer Bleeding1
4CompletedTreatmentIndigestion1
4CompletedTreatmentOsteoarthritis (OA) / Rheumatoid Arthritis1
4CompletedTreatmentPeptic Ulcers1
4Not Yet RecruitingBasic ScienceProbiotics1
4RecruitingBasic ScienceType 2 Diabetes Mellitus1
4RecruitingTreatmentChronic Low Back Pain (CLBP)2
4RecruitingTreatmentCrohn's Disease (CD) / Ulcerative Colitis (UC)1
4RecruitingTreatmentEPS / Gastro-esophageal Reflux Disease (GERD)1
4RecruitingTreatmentHeartburn1
4RecruitingTreatmentTinea Cruris / Tinea Pedis1
4SuspendedTreatmentRotator Cuff Syndrome1
4TerminatedPreventionLaryngopharyngeal Reflux / Throat Pain1
4TerminatedTreatmentPeptic ulcer haemorrhage1
4TerminatedTreatmentReflux, Gastroesophageal1
4Unknown StatusPreventionAcute Coronary Syndromes (ACS)1
4Unknown StatusTreatmentBacterial Infection Due to Helicobacter Pylori (H. Pylori)1
4Unknown StatusTreatmentCDA Type I1
4Unknown StatusTreatmentCoronary Artery Disease1
4Unknown StatusTreatmentGastro-esophageal Reflux Disease (GERD)1
4Unknown StatusTreatmentNonvariceal Upper Gastrointestinal Bleeding1
4WithdrawnPreventionPeptic Ulcers1
4WithdrawnTreatmentCoronary Artery Disease1
4WithdrawnTreatmentEustachian Tube Dysfunction / Laryngopharyngeal Reflux1
4WithdrawnTreatmentGastroduodenal Ulcers / Marginal Ulcers / Peptic ulcer haemorrhage1
4WithdrawnTreatmentLaryngopharyngeal Reflux1
Not AvailableActive Not RecruitingNot AvailableGastroduodenal Ulcers / Marginal Ulcers / Peptic ulcer haemorrhage1
Not AvailableCompletedNot AvailableAnthocyanin Metabolism1
Not AvailableCompletedNot AvailableAspirin Blood Level / Proton Pump Inhiditor Treatment1
Not AvailableCompletedNot AvailableChronic Laryngitis / Gastro-esophageal Reflux Disease (GERD)1
Not AvailableCompletedNot AvailableCommunity Acquired Pneumonia (CAP) / Gastro-esophageal Reflux Disease (GERD)1
Not AvailableCompletedBasic ScienceDrug-Drug Interaction (DDI) / Healthy Volunteers1
Not AvailableCompletedBasic ScienceGastroesophageal Reflux Disease1
Not AvailableCompletedDiagnosticBile Reflux / Gastroesophageal Reflux Disease / Indigestion1
Not AvailableCompletedDiagnosticHealthy Volunteers / Liver Cirrhosis1
Not AvailableCompletedPreventionCritical Illness1
Not AvailableCompletedTreatmentBacterial Infection Due to Helicobacter Pylori (H. Pylori)2
Not AvailableCompletedTreatmentBacterial Infection Due to Helicobacter Pylori (H. Pylori) / Functional Dyspepsia1
Not AvailableCompletedTreatmentGastric MALT Lymphoma1
Not AvailableCompletedTreatmentMetabolism of Clopidogrel1
Not AvailableNot Yet RecruitingNot AvailableGastro-esophageal Reflux Disease (GERD)1
Not AvailableRecruitingNot AvailableDepression1
Not AvailableRecruitingBasic ScienceClostridium Difficile Infection (CDI)1
Not AvailableRecruitingDiagnosticNon-erosive Reflux Disease (NERD) / Reflux, Gastroesophageal1
Not AvailableTerminatedScreeningCytochrome P450 Phenotype and Genotype Metrics1
Not AvailableUnknown StatusTreatmentEsophagus, Barrett / Reflux, Gastroesophageal1
Not AvailableWithdrawnDiagnosticGastroesophageal Reflux Disease / Indigestion / Non Erosive Reflux Disease1

Pharmacoeconomics

Manufacturers
  • Apotex inc
  • Dr reddys laboratories ltd
  • Impax laboratories inc
  • Kremers urban development co
  • Lek pharmaceuticals d d
  • Mylan pharmaceuticals inc
  • Sandoz inc
  • Watson laboratories inc florida
  • Astrazeneca lp
  • Dexcel pharma technologies ltd
  • Santarus, Inc.
Packagers
  • Aidarex Pharmacuticals LLC
  • Altura Pharmaceuticals Inc.
  • Amerisource Health Services Corp.
  • Apotex Inc.
  • A-S Medication Solutions LLC
  • Astra Pharma Inc.
  • AstraZeneca Inc.
  • Atlantic Biologicals Corporation
  • Blenheim Pharmacal
  • Bryant Ranch Prepack
  • Cardinal Health
  • Caremark LLC
  • Comprehensive Consultant Services Inc.
  • Concern Stirol
  • Contract Packaging Resources Inc.
  • Corepharma LLC
  • Coupler Enterprises Inc.
  • CVS Pharmacy
  • Dept Health Central Pharmacy
  • Dexcel Ltd.
  • DHHS Program Support Center Supply Service Center
  • Dispensing Solutions
  • Diversified Healthcare Services Inc.
  • Doctor Reddys Laboratories Ltd.
  • Ftl International Inc.
  • Global Pharmaceuticals
  • Golden State Medical Supply Inc.
  • H.J. Harkins Co. Inc.
  • Heartland Repack Services LLC
  • Impax Laboratories Inc.
  • Innoviant Pharmacy Inc.
  • Kaiser Foundation Hospital
  • Keltman Pharmaceuticals Inc.
  • Laboratorios Dr Esteve SA
  • Lake Erie Medical and Surgical Supply
  • Lek Pharmaceuticals Inc.
  • Major Pharmaceuticals
  • Mckesson Corp.
  • Medisca Inc.
  • Medsource Pharmaceuticals
  • Merck & Co.
  • Merial Inc.
  • Murfreesboro Pharmaceutical Nursing Supply
  • Mylan
  • Nucare Pharmaceuticals Inc.
  • Palmetto Pharmaceuticals Inc.
  • Par Pharmaceuticals
  • Patheon Inc.
  • PD-Rx Pharmaceuticals Inc.
  • Perrigo Co.
  • Physicians Total Care Inc.
  • Preferred Pharmaceuticals Inc.
  • Prepak Systems Inc.
  • Prescript Pharmaceuticals
  • Procter & Gamble
  • Ranbaxy Laboratories
  • Rebel Distributors Corp.
  • Remedy Repack
  • S&P Healthcare
  • Sandhills Packaging Inc.
  • Sandoz
  • Santarus Inc.
  • Schwarz Pharma Inc.
  • Southwood Pharmaceuticals
  • St Mary's Medical Park Pharmacy
  • Stat Rx Usa
  • Teva Pharmaceutical Industries Ltd.
  • Torpharm Inc.
  • UDL Laboratories
  • Vangard Labs Inc.
  • Watson Pharmaceuticals
Dosage forms
FormRouteStrength
Capsule, delayed releaseOral20 mg
Tablet, orally disintegrating, delayed releaseOral20 mg/1
Tablet, delayed releaseOral10 mg
Tablet, delayed releaseOral20 mg
Capsule, delayed releaseOral40 mg
Kit
Kit
CapsuleOral10 mg/1
CapsuleOral20 mg/1
CapsuleOral40 mg/1
Capsule, delayed releaseOral10 mg/1
Capsule, delayed releaseOral20 mg/1
Capsule, delayed releaseOral40 mg/1
Capsule, delayed release pelletsOral10 mg/1
Capsule, delayed release pelletsOral20 mg/1
Capsule, delayed release pelletsOral40 mg/1
Capsule, gelatin coatedOral
Powder, for suspensionOral
Tablet, delayed releaseOral20 mg/1
CapsuleOral20.6 mg/1
Capsule, delayed releaseOral20.6 mg/1
Granule, delayed releaseOral10 mg/1
Granule, delayed releaseOral2.5 mg/1
Tablet, delayed releaseOral20.6 mg/1
Capsule, delayed releaseOral10 mg
Tablet, film coatedOral
CapsuleOral
Prices
Unit descriptionCostUnit
PriLOSEC 30 20 mg Delayed Release Capsule Bottle459.99USD bottle
Zegerid 30 20-1680 mg Packets Packet224.27USD packet
Zegerid 30 40-1680 mg Packets Packet224.27USD packet
PriLOSEC 30 10 mg Delayed Release Capsule Bottle174.37USD bottle
Omeprazole 28 20 mg Enteric Coated Tabs Box25.99USD box
PriLOSEC OTC 14 20 mg Enteric Coated Tabs Box19.99USD box
PriLOSEC 40 mg Delayed Release Capsule9.59USD capsule
Prilosec dr 40 mg capsule9.22USD capsule
Omeprazole 40 mg Delayed Release Capsule7.69USD capsule
Zegerid 40-1100 mg capsule7.48USD capsule
Zegerid 20 mg capsule7.19USD capsule
Zegerid 40 mg capsule6.46USD capsule
Prilosec dr 20 mg capsule6.24USD capsule
Prilosec 20 mg capsule dr6.15USD capsule
Prilosec dr 10 mg capsule5.59USD capsule
Omeprazole powder5.05USD g
Omeprazole 20 mg Delayed Release Capsule4.32USD capsule
Omeprazole 10 mg Delayed Release Capsule3.13USD capsule
Losec (Sustained-Release Tablet) 20 mg Capsule/Sustained Release Tablet2.48USD tablet
Losec (Sustained-Release Tablet) 10 mg Capsule/Sustained Release Tablet1.97USD tablet
Losec (Sustained-Release Capsule) 20 mg Capsule/Sustained Release Tablet1.24USD tablet
Apo-Omeprazole 20 mg Capsule/Sustained Release Tablet1.15USD tablet
Mylan-Omeprazole 20 mg Capsule/Sustained Release Tablet1.15USD tablet
Pms-Omeprazole (Delayed Release Tablet) 20 mg Capsule/Sustained Release Tablet1.15USD tablet
Pms-Omeprazole (Sustained-Release Capsule) 20 mg Capsule/Sustained Release Tablet1.15USD tablet
Ratio-Omeprazole (Sustained-Release Tablet) 20 mg Capsule/Sustained Release Tablet1.15USD tablet
Sandoz Omeprazole (Sustained-Release Capsule) 20 mg Capsule/Sustained Release Tablet1.15USD tablet
Mylan-Omeprazole 10 mg Capsule/Sustained Release Tablet0.86USD tablet
Sandoz Omeprazole (Sustained-Release Capsule) 10 mg Capsule/Sustained Release Tablet0.86USD tablet
Zegerid otc 20-1100 mg capsule0.78USD capsule
Prilosec otc 20 mg tablet0.76USD tablet
Omeprazole dr 20 mg tablet0.66USD tablet
CVS Pharmacy omeprazole dr 20 mg tablet0.53USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5690960No1994-11-252014-11-25Us
CA2180535No2004-03-232014-01-05Canada
CA1338377No1996-06-112013-06-11Canada
US6489346No1996-07-162016-07-16Us
US6699885No1996-07-162016-07-16Us
USRE45198No1996-07-162016-07-16Us
US6645988No1996-07-162016-07-16Us
US7399772No1996-07-162016-07-16Us
US6150380Yes1999-05-102019-05-10Us
US6191148Yes1999-04-092019-04-09Us
US6147103Yes1999-04-092019-04-09Us
US6166213Yes1999-04-092019-04-09Us
US5900424Yes1996-11-042016-11-04Us
US6428810Yes2000-05-032020-05-03Us
US9023391No2005-08-162025-08-16Us
US6403616No1999-11-152019-11-15Us
US5817338No1995-10-062015-10-06Us
US5840737No1996-07-152016-07-15Us
US6780882No1996-07-152016-07-15Us
US6926907No2003-02-282023-02-28Us
US9539214No2013-03-132033-03-13Us
US9364439No2002-05-312022-05-31Us
US8206741No2003-02-282023-02-28Us
US9987231No2013-01-022033-01-02Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)155 °CFDA label
water solubilityVery slightly soluble FDA label
logP2.23SANGSTER (1994)
Predicted Properties
PropertyValueSource
Water Solubility0.359 mg/mLALOGPS
logP1.66ALOGPS
logP2.43ChemAxon
logS-3ALOGPS
pKa (Strongest Acidic)9.29ChemAxon
pKa (Strongest Basic)4.77ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area77.1 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity93.66 m3·mol-1ChemAxon
Polarizability37.45 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9968
Blood Brain Barrier-0.6326
Caco-2 permeable+0.8867
P-glycoprotein substrateNon-substrate0.5573
P-glycoprotein inhibitor IInhibitor0.6622
P-glycoprotein inhibitor IINon-inhibitor0.968
Renal organic cation transporterNon-inhibitor0.542
CYP450 2C9 substrateNon-substrate0.7838
CYP450 2D6 substrateSubstrate0.6175
CYP450 3A4 substrateSubstrate0.6901
CYP450 1A2 substrateInhibitor0.7505
CYP450 2C9 inhibitorNon-inhibitor0.907
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorInhibitor0.8994
CYP450 3A4 inhibitorInhibitor0.796
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.7895
Ames testNon AMES toxic0.5692
CarcinogenicityNon-carcinogens0.8318
BiodegradationNot ready biodegradable0.9778
Rat acute toxicity2.2254 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.719
hERG inhibition (predictor II)Non-inhibitor0.8977
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-002f-0900000000-412912cbbcdbd1b34699
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0002-0901000000-189e81fb724041d50498
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0f6t-0900000000-db101d248a4e861d4c3b
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0uds-0900000000-f579fb74ac97c56dd3eb
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-000i-0900000000-eefbf9686f0313da581e
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-000i-0900000000-363d6954875894f433ba
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0f6t-1900000000-d8c64d496f1d9b3ed465
MS/MS Spectrum - , positiveLC-MS/MSsplash10-014i-1669000000-51f9342d7e4bbd0356b2
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0f6t-0900000000-d21755acc44ff2d29cfa
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0f80-2900000000-9989d19c171c612ea3dc
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0002-0900000000-f74adb7f41e2d390b602
1H NMR Spectrum1D NMRNot Applicable
[1H,13C] 2D NMR Spectrum2D NMRNot Applicable

Taxonomy

Description
This compound belongs to the class of organic compounds known as sulfinylbenzimidazoles. These are polycyclic aromatic compounds containing a sulfinyl group attached at the position 2 of a benzimidazole moiety.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Benzimidazoles
Sub Class
Sulfinylbenzimidazoles
Direct Parent
Sulfinylbenzimidazoles
Alternative Parents
Anisoles / Methylpyridines / Alkyl aryl ethers / Imidazoles / Heteroaromatic compounds / Sulfoxides / Sulfinyl compounds / Azacyclic compounds / Organopnictogen compounds / Organonitrogen compounds
show 2 more
Substituents
Sulfinylbenzimidazole / Anisole / Alkyl aryl ether / Methylpyridine / Pyridine / Benzenoid / Azole / Imidazole / Heteroaromatic compound / Sulfoxide
show 12 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
aromatic ether, sulfoxide, pyridines, benzimidazoles (CHEBI:77260)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Sodium:potassium-exchanging atpase activity
Specific Function
Catalyzes the hydrolysis of ATP coupled with the exchange of H(+) and K(+) ions across the plasma membrane. Responsible for acid production in the stomach.
Gene Name
ATP4A
Uniprot ID
P20648
Uniprot Name
Potassium-transporting ATPase alpha chain 1
Molecular Weight
114117.74 Da
References
  1. Tajima A, Koizumi K, Suzuki K, Higashi N, Takahashi M, Shimada T, Terano A, Hiraishi H, Kuwayama H: Proton pump inhibitors and recurrent bleeding in peptic ulcer disease. J Gastroenterol Hepatol. 2008 Dec;23 Suppl 2:S237-41. doi: 10.1111/j.1440-1746.2008.05557.x. [PubMed:19120905]
  2. Shi S, Klotz U: Proton pump inhibitors: an update of their clinical use and pharmacokinetics. Eur J Clin Pharmacol. 2008 Oct;64(10):935-51. doi: 10.1007/s00228-008-0538-y. Epub 2008 Aug 5. [PubMed:18679668]
  3. Kirchheiner J, Glatt S, Fuhr U, Klotz U, Meineke I, Seufferlein T, Brockmoller J: Relative potency of proton-pump inhibitors-comparison of effects on intragastric pH. Eur J Clin Pharmacol. 2009 Jan;65(1):19-31. doi: 10.1007/s00228-008-0576-5. Epub 2008 Oct 17. [PubMed:18925391]
  4. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Agonist
General Function
Transcription regulatory region dna binding
Specific Function
Ligand-activated transcriptional activator. Binds to the XRE promoter region of genes it activates. Activates the expression of multiple phase I and II xenobiotic chemical metabolizing enzyme genes...
Gene Name
AHR
Uniprot ID
P35869
Uniprot Name
Aryl hydrocarbon receptor
Molecular Weight
96146.705 Da
References
  1. Dzeletovic N, McGuire J, Daujat M, Tholander J, Ema M, Fujii-Kuriyama Y, Bergman J, Maurel P, Poellinger L: Regulation of dioxin receptor function by omeprazole. J Biol Chem. 1997 May 9;272(19):12705-13. [PubMed:9139728]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and im...
Gene Name
CYP2C19
Uniprot ID
P33261
Uniprot Name
Cytochrome P450 2C19
Molecular Weight
55930.545 Da
References
  1. Foti RS, Wahlstrom JL: CYP2C19 inhibition: the impact of substrate probe selection on in vitro inhibition profiles. Drug Metab Dispos. 2008 Mar;36(3):523-8. Epub 2007 Nov 29. [PubMed:18048485]
  2. Li XQ, Andersson TB, Ahlstrom M, Weidolf L: Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos. 2004 Aug;32(8):821-7. [PubMed:15258107]
  3. Li XQ, Weidolf L, Simonsson R, Andersson TB: Enantiomer/enantiomer interactions between the S- and R- isomers of omeprazole in human cytochrome P450 enzymes: major role of CYP2C19 and CYP3A4. J Pharmacol Exp Ther. 2005 Nov;315(2):777-87. Epub 2005 Aug 10. [PubMed:16093273]
  4. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  5. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  6. Yamazaki H, Inoue K, Shaw PM, Checovich WJ, Guengerich FP, Shimada T: Different contributions of cytochrome P450 2C19 and 3A4 in the oxidation of omeprazole by human liver microsomes: effects of contents of these two forms in individual human samples. J Pharmacol Exp Ther. 1997 Nov;283(2):434-42. [PubMed:9353355]
  7. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Details
2. Cytochrome P450 3A4
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
Inducer
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Li XQ, Weidolf L, Simonsson R, Andersson TB: Enantiomer/enantiomer interactions between the S- and R- isomers of omeprazole in human cytochrome P450 enzymes: major role of CYP2C19 and CYP3A4. J Pharmacol Exp Ther. 2005 Nov;315(2):777-87. Epub 2005 Aug 10. [PubMed:16093273]
  2. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  3. Botsch S, Gautier JC, Beaune P, Eichelbaum M, Kroemer HK: Identification and characterization of the cytochrome P450 enzymes involved in N-dealkylation of propafenone: molecular base for interaction potential and variable disposition of active metabolites. Mol Pharmacol. 1993 Jan;43(1):120-6. [PubMed:8423765]
  4. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  5. Turpeinen M, Uusitalo J, Jalonen J, Pelkonen O: Multiple P450 substrates in a single run: rapid and comprehensive in vitro interaction assay. Eur J Pharm Sci. 2005 Jan;24(1):123-32. [PubMed:15626586]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
Inducer
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A2
Uniprot ID
P05177
Uniprot Name
Cytochrome P450 1A2
Molecular Weight
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Details
4. Cytochrome P450 2C9
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
Molecular Weight
55627.365 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C18
Uniprot ID
P33260
Uniprot Name
Cytochrome P450 2C18
Molecular Weight
55710.075 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C8
Uniprot ID
P10632
Uniprot Name
Cytochrome P450 2C8
Molecular Weight
55824.275 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, nad(p)h as one donor, and incorporation of one atom of oxygen
Specific Function
Catalyzes the side-chain cleavage reaction of cholesterol to pregnenolone.
Gene Name
CYP11A1
Uniprot ID
P05108
Uniprot Name
Cholesterol side-chain cleavage enzyme, mitochondrial
Molecular Weight
60101.87 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inducer
General Function
Vitamin d 24-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A1
Uniprot ID
P04798
Uniprot Name
Cytochrome P450 1A1
Molecular Weight
58164.815 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inducer
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1B1
Uniprot ID
Q16678
Uniprot Name
Cytochrome P450 1B1
Molecular Weight
60845.33 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inducer
General Function
Organic anion transmembrane transporter activity
Specific Function
May act as an inducible transporter in the biliary and intestinal excretion of organic anions. Acts as an alternative route for the export of bile acids and glucuronides from cholestatic hepatocyte...
Gene Name
ABCC3
Uniprot ID
O15438
Uniprot Name
Canalicular multispecific organic anion transporter 2
Molecular Weight
169341.14 Da
References
  1. Hitzl M, Klein K, Zanger UM, Fritz P, Nussler AK, Neuhaus P, Fromm MF: Influence of omeprazole on multidrug resistance protein 3 expression in human liver. J Pharmacol Exp Ther. 2003 Feb;304(2):524-30. [PubMed:12538803]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Pauli-Magnus C, Rekersbrink S, Klotz U, Fromm MF: Interaction of omeprazole, lansoprazole and pantoprazole with P-glycoprotein. Naunyn Schmiedebergs Arch Pharmacol. 2001 Dec;364(6):551-7. [PubMed:11770010]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Xenobiotic-transporting atpase activity
Specific Function
High-capacity urate exporter functioning in both renal and extrarenal urate excretion. Plays a role in porphyrin homeostasis as it is able to mediates the export of protoporhyrin IX (PPIX) both fro...
Gene Name
ABCG2
Uniprot ID
Q9UNQ0
Uniprot Name
ATP-binding cassette sub-family G member 2
Molecular Weight
72313.47 Da
References
  1. Breedveld P, Zelcer N, Pluim D, Sonmezer O, Tibben MM, Beijnen JH, Schinkel AH, van Tellingen O, Borst P, Schellens JH: Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles: potential role for breast cancer resistance protein in clinical drug-drug interactions. Cancer Res. 2004 Aug 15;64(16):5804-11. [PubMed:15313923]
  2. Suzuki K, Doki K, Homma M, Tamaki H, Hori S, Ohtani H, Sawada Y, Kohda Y: Co-administration of proton pump inhibitors delays elimination of plasma methotrexate in high-dose methotrexate therapy. Br J Clin Pharmacol. 2009 Jan;67(1):44-9. doi: 10.1111/j.1365-2125.2008.03303.x. Epub 2008 Nov 17. [PubMed:19076159]

Drug created on June 13, 2005 07:24 / Updated on August 15, 2018 09:38